• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优质疫苗的可及性:行业视角

Availability of quality vaccines: the industrial point of view.

作者信息

Vandersmissen W

机构信息

SmithKline Beecham Biologicals, Rixensart, Belgium.

出版信息

Vaccine. 1992;10(13):955-7. doi: 10.1016/0264-410x(92)90333-f.

DOI:10.1016/0264-410x(92)90333-f
PMID:1471420
Abstract

Availability of vaccines may be temporarily affected by sudden peak demand, coming on top of the vast increases of regular demand that the world has witnessed; this must be addressed by sound planning, and flexibility both from manufacturers and users. Temporary shortages are not structural in nature, and capacity is at hand to meet demand. Transfer of technology to developing nations is not likely to make the supply of vaccines of good quality any easier, faster or substantially cheaper, as the constraints that determine vaccine manufacture will not change merely by locating a production unit in a developing nation.

摘要

疫苗的供应可能会因突然出现的需求高峰而暂时受到影响,而在此之前全球常规需求已大幅增长;这必须通过合理规划以及制造商和用户双方的灵活性来解决。临时短缺并非结构性问题,现有产能足以满足需求。向发展中国家转让技术不太可能使优质疫苗的供应变得更容易、更快或大幅降低成本,因为决定疫苗生产的制约因素不会仅仅因为在发展中国家设立一个生产单位就发生改变。

相似文献

1
Availability of quality vaccines: the industrial point of view.优质疫苗的可及性:行业视角
Vaccine. 1992;10(13):955-7. doi: 10.1016/0264-410x(92)90333-f.
2
The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade.全球疫苗生产能力。未来十年生产商之间的竞争与合作前景。
Int J Technol Assess Health Care. 1994 Winter;10(1):39-46. doi: 10.1017/s0266462300013969.
3
Availability of quality vaccines: policies of a non-government organization.优质疫苗的可及性:一个非政府组织的政策
Vaccine. 1992;10(13):958-60. doi: 10.1016/0264-410x(92)90334-g.
4
Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.发展中国家疫苗制造商网络:生产高质量疫苗,让所有人都买得起,从而造福大众。
Vaccine. 2013 Apr 18;31 Suppl 2:B176-83. doi: 10.1016/j.vaccine.2012.11.060.
5
The Children's Vaccine Initiative and vaccine supply: the role of the public sector.儿童疫苗倡议与疫苗供应:公共部门的作用
Vaccine. 1992;10(13):909-10. doi: 10.1016/0264-410x(92)90323-c.
6
Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.发展中国家疫苗生产商网络(DCVMN):参与加强疫苗研发和获取力度。会议报告 2012 年。
Vaccine. 2013 Jun 28;31(31):3111-5. doi: 10.1016/j.vaccine.2013.04.082. Epub 2013 May 15.
7
The countries' point of view.各国的观点。
Vaccine. 1992;10(13):954. doi: 10.1016/0264-410x(92)90332-e.
8
The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.发展中国家疫苗制造商网络(DCVMN)是确保发展中国家能够获得疫苗的关键支持者。
Vaccine. 2008 Mar 20;26(13):1611-5. doi: 10.1016/j.vaccine.2008.01.034. Epub 2008 Feb 6.
9
The global vaccine enterprise: a developing world perspective.全球疫苗企业:发展中世界视角
Nat Med. 1998 May;4(5 Suppl):503-5. doi: 10.1038/nm0598supp-503.
10
Availability of vaccines of an assured quality.有质量保证的疫苗供应。
Vaccine. 1992;10(13):952-3. doi: 10.1016/0264-410x(92)90331-d.

引用本文的文献

1
From lab to mass production: a policy for enabling the licensing of mRNA vaccines.从实验室到大规模生产:mRNA 疫苗许可的政策。
Front Public Health. 2023 May 18;11:1151713. doi: 10.3389/fpubh.2023.1151713. eCollection 2023.